复方激素避孕药使用者的缺血性卒中:一项丹麦登记研究
基于丹麦全国登记数据,纳入2004至2021年18至49岁非妊娠女性1 711 757例、共14 697 788人年,比较复方激素避孕药(CHC)使用者与非使用者(未用激素避孕)的缺血性卒中发生率的比值(IRR)。含<50微克炔雌醇的CHC使用者校正IRR为1.77(95%CI 1.62-1.93)。第四代孕激素CHC使用者IRR比第二代低30%(校正IRR 0.70 [95%CI 0.50-0.98])。
要点
- 含<50微克炔雌醇的CHC使用者缺血性卒中校正IRR为1.77(95%CI 1.62-1.93),对照为未用激素避孕者。
- 30-40微克与≤20微克炔雌醇CHC之间IRR无差异。
- 第四代孕激素CHC使用者IRR比第二代低30%(校正IRR 0.70 [95%CI 0.50-0.98]),第三代与第二代无显著差异(校正IRR 1.14 [95%CI 0.97-1.35])。
核心结论
- 使用CHC与缺血性卒中IRR升高1.77相关(95%CI 1.62-1.93),对照为未用激素避孕者。
- 在含<50微克炔雌醇的CHC使用者中,IRR与炔雌醇含量无关。
- 第四代孕激素CHC使用者IRR比第二代低30%(校正IRR 0.70 [95%CI 0.50-0.98])。
研究设计与样本
- 基于丹麦登记数据的队列研究,覆盖2004至2021年丹麦全国18至49岁女性。
- 共1 711 757名非妊娠女性贡献14 697 788人年。
- 采用泊松回归模型,校正年龄、教育、民族、日历年及用于危险因素的药物。
- 比较含<50微克炔雌醇的CHC使用者与非使用者(未用激素避孕)的缺血性卒中IRR。
- 分析按炔雌醇含量(30-40微克与≤20微克)、孕激素代别(第二、三、四代)及给药方式(单相与序贯)分层比较。
主要发现
- 含<50微克炔雌醇CHC使用者校正IRR为1.77(95%CI 1.62-1.93),对照为未用激素避孕者。
- 30-40微克与≤20微克炔雌醇CHC之间IRR无差异。
- CHC使用者与非使用者校正发生率差从18至24岁的每年每10万女性1例到≥45岁的每年每10万女性24例。
- 第四代孕激素CHC使用者发生率比第二代低30%,校正IRR为0.70(95%CI 0.50-0.98)。
- 第三代孕激素CHC使用者校正IRR为1.14(95%CI 0.97-1.35),与第二代使用者无显著差异。
关键数值与推荐
- 含<50微克炔雌醇CHC使用者校正IRR 1.77(95%CI 1.62-1.93),对照为未用激素避孕者。
- 第四代与第二代孕激素CHC比较校正IRR 0.70(95%CI 0.50-0.98)。
- 第三代与第二代孕激素CHC比较校正IRR 1.14(95%CI 0.97-1.35),无显著差异。
- 校正发生率差:18至24岁每年每10万女性1例,≥45岁每年每10万女性24例。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The combined hormonal contraceptive (CHC) with ethinylestradiol and progestins is the most widely used contraceptive method among young women and is used by millions worldwide. However, uncertainties exist about the risk of ischemic stroke associated with the use of CHCs with low-dose ethinylestradiol (<50-µg ethinylestradiol) and with the newest fourth-generation progestins that have only been sparsely investigated for the risk of ischemic stroke. METHODS: In this cohort study based on Danish registries covering the entire Danish female population aged 18 to 49 years from 2004 to 2021, we investigated incidence rate ratios (IRRs) of ischemic stroke using CHCs compared with nonuse of hormonal contraceptives. Analyses focused on comparing CHCs based on ethinylestradiol content (30-40- versus ≤20-μg ethinylestradiol), progestin generation (second, third, and fourth) in CHCs, and route of administration (monophasic versus sequential). Poisson regression models adjusting for age, education, ethnicity, calendar year, and medication used for risk factors were utilized. RESULTS: In total, 1 711 757 nonpregnant women contributed 14 697 788 person-years to the investigation. For users of CHCs containing <50-µg ethinylestradiol, the adjusted IRR was increased by 1.77 (95% CI, 1.62-1.93) compared with nonusers of hormonal contraceptives. IRR did not differ between CHCs with 30- to 40- and ≤20-µg ethinylestradiol. Adjusted incidence rate difference between CHC users and nonusers of hormonal contraceptives ranged from 1 in 100 000 women per year in 18 to 24 years of age to 24 in 100 000 women per year in ≥45 years of age. Incidence rate in users of fourth-generation CHCs was 30% lower than that of second-generation CHCs adjusted IRR (0.70 [95% CI, 0.50-0.98]). IRR for users of third-generation CHCs did not differ significantly from that of second-generation users adjusted IRR (1.14 [95% CI, 0.97-1.35]). CONCLUSIONS: Use of CHCs was associated with a 1.77 higher IRR of ischemic stroke. IRR did not relate to ethinylestradiol content in users of CHCs with <50-µg ethinylestradiol. IRR was 30% lower in users of fourth-generation than in users of second-generation CHCs.
引用
- Letnar G, Andersen KK, Olsen TS, et al. Ischemic Stroke in Users of Combined Hormonal Contraceptives: A Danish Registry Study. Stroke. 2024. PMID: 39648905. doi:10.1161/STROKEAHA.124.049252
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。